ZHAOKE OPHTH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025

Feb 5 21:02 ET

ZHAOKE OPHTH-B: VOLUNTARY ANNOUNCEMENT - ENTERING INTO DISTRIBUTIONAGREEMENT WITH AFT PHARMACEUTICALS TO COMMERCIALIZEBRIMOCHOL TM PF IN AUSTRALIA AND NEW ZEALAND

Jan 13 04:40 ET

ZHAOKE OPHTH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024

Jan 3 03:32 ET

ZHAOKE OPHTH-B: VOLUNTARY ANNOUNCEMENT -NMPA ACCEPTANCE OF ABBREVIATED NEW DRUGAPPLICATION FOR NVK002 FOR TREATMENT OFMYOPIA PROGRESSION IN CHILDREN

Jan 2 05:40 ET

ZHAOKE OPHTH-B: VOLUNTARY ANNOUNCEMENT - POSITIVE TOP-LINE RESULTS FROM TAB014 PHASE III CLINICAL TRIAL FOR THE TREATMENT OF wAMD

Jan 1 19:01 ET

ZHAOKE OPHTH-B: INSIDE INFORMATION - MARKETING AUTHORIZATIONS OBTAINED FROM THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR LATANOPROST EYE DROP, TRAVOPROST EYE DROP, AND TRAVOPROST TIMOLOL EYE DROP

Dec 9, 2024 04:22 ET

ZHAOKE OPHTH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024

Dec 2, 2024 23:05 ET

ZHAOKE OPHTH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024

Nov 3, 2024 22:42 ET

ZHAOKE OPHTH-B: VOLUNTARY ANNOUNCEMENT - POSITIVE TOP-LINE RESULTS FROM NVK002 TWO-YEAR PHASE III CLINICAL TRIAL (CHINA CHAMP) IN CHINA FOR THE TREATMENT OF MYOPIA PROGRESSION IN CHILDREN

Oct 23, 2024 05:45 ET

ZHAOKE OPHTH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024

Oct 1, 2024 22:45 ET

ZHAOKE OPHTH-B: VOLUNTARY ANNOUNCEMENT - COMPLETION OF TAB014 PHASE III CLINICAL TRIAL LAST PATIENT LAST VISIT IN CHINA

Sep 26, 2024 04:30 ET

ZHAOKE OPHTH-B: NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM

Sep 23, 2024 04:45 ET

ZHAOKE OPHTH-B: NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM

Sep 23, 2024 04:41 ET

ZHAOKE OPHTH-B: 2024 Interim Report

Sep 23, 2024 04:33 ET

ZHAOKE OPHTH-B: INSIDE INFORMATION - MARKETING AUTHORIZATION FORBIMATOPROST EYE DROP OBTAINED FROM THENATIONAL MEDICAL PRODUCTS ADMINISTRATION

Sep 19, 2024 18:10 ET

ZHAOKE OPHTH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024

Sep 2, 2024 22:37 ET

ZHAOKE OPHTH-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024

Aug 29, 2024 06:28 ET

ZHAOKE OPHTH-B: NOTICE OF BOARD MEETING

Aug 16, 2024 05:34 ET

ZHAOKE OPHTH-B: PROFIT ALERT - REDUCTION IN LOSS

Aug 14, 2024 10:34 ET

ZHAOKE OPHTH-B: VOLUNTARY ANNOUNCEMENT - APPROVAL OF INVESTIGATIONAL NEW DRUG APPLICATION FOR PHASE III CLINICAL TRIAL OF CYCLOSPORINE A (CsA) OPHTHALMIC GEL BY NMPA AND COMPLETION OF NVK002 PHASE III CHINA-CHAMP LAST PATIENT LAST VISIT IN CHINA

Aug 11, 2024 19:54 ET